Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 16,842 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Complication Clear all
Recruiting Not applicable Interventional

Multimodal Analgesic Regimen for Total Hip Arthroplasty: An Initiative to Minimize Postoperative Opioid Use

NCT07672808
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip
Interventions
Standard Multimodal Analgesic Regimen with Opioid Prescription, Opioid-Reduced Multimodal Analgesic Regimen with Printed Prescription
Drug · Behavioral
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 11:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Pilot Study of the Provant Therapy System in Subjects With Diabetic Foot Ulcers

NCT00761176
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
The Provant Therapy System
Device
Lead sponsor
Regenesis Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Oct 23, 2026, 11:29 AM EDT
Recruiting No phase listed Observational

Natural History of Noncirrhotic Portal Hypertension

NCT02417740
View directory record Official record
Conditions
Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 11:29 AM EDT
Terminated Phase 3 Interventional Results available

Management Of Pain After Cesarean Trial

NCT03929640
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use
Interventions
Acetaminophen, Placebo, Ibuprofen
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 2 Interventional Results available

CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer

NCT00610740
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Ovarian Cancer
Interventions
topical gemcitabine hydrochloride, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 23, 2026, 11:29 AM EDT
Not yet recruiting Not applicable Interventional

The LARC Robot Simplifies Renal Access In Percutaneous Nephrolithotomy

NCT07211555
View directory record Official record
Conditions
Renal Stone Disease, Kidney Calculi, Refractory Kidney Stones, Kidney Stones
Interventions
LARC Robotic System (Micromate™ Version 3.0)
Device
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 2 Interventional

The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis

NCT03129126
View directory record Official record
Conditions
Hemorrhagic Cystitis
Interventions
LP-10
Drug
Lead sponsor
Lipella Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Tucson, Arizona • San Francisco, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 1 Interventional

Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors

NCT00303940
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
carboplatin, talabostat mesylate, temozolomide, pharmacological study
Drug · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
2 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Not applicable Interventional Results available

Transpelvic Magnetic Stimulation to Improve Urogenital Function

NCT04488068
View directory record Official record
Conditions
Prostate Cancer, Erectile Dysfunction
Interventions
Sham Magnetic stimulation
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 80 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 23, 2026, 11:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate

NCT02743650
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium bicarbonate
Dietary Supplement
Lead sponsor
University of Utah
Other
Eligibility
50 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Measuring Practice Pattern Changes and Clinical Utility of a Novel Test for Preeclampsia

NCT04204018
View directory record Official record
Conditions
Pre-Eclampsia
Interventions
Experimental Arm
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 23, 2026, 11:29 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Preeclampsia: A Marker for Future Cardiovascular Risk in Women

NCT01519297
View directory record Official record
Conditions
Preeclampsia, Pregnancy Induced Hypertension
Interventions
Irbesartan
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 23, 2026, 11:29 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

NCT04241185
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
Pembrolizumab, Conventional Radiotherapy (Bladder only), Conventional Radiotherapy (Bladder and pelvic nodes), Hypofractionated Radiotherapy (Bladder only), Cisplatin, Fluorouracil (5-FU), Mitomycin C (MMC), Gemcitabine, Placebo to Pembrolizumab
Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
24
States / cities
Washington D.C., District of Columbia • Bay Pines, Florida • Orlando, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer

NCT02865135
View directory record Official record
Conditions
Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus
Interventions
DPX-E7 vaccine, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 2Phase 3 Interventional

NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00061776
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases, Shingles
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Not applicable Interventional

Listening to Mom in the NICU: Neural, Clinical and Language Outcomes

NCT02847689
View directory record Official record
Conditions
Premature Birth
Interventions
Language Treatment, Control Treatment
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
24 Weeks to 31 Weeks
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 1 Interventional

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05521191
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
Interventions
RGLS8429, Placebo
Drug
Lead sponsor
Regulus Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
21
States / cities
Mesa, Arizona • Los Angeles, California • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 23, 2026, 11:29 AM EDT
Completed No phase listed Observational

Mechanisms and Treatment of Intradialytic Hypertension - Sodium

NCT01371890
View directory record Official record
Conditions
Hemodialysis, End-stage Renal Disease, Hypertension, Intradialytic Hypertension
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 3 Interventional

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

NCT00770081
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
vildagliptin, sitagliptin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 4 Interventional Results available

Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma

NCT00414765
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Metastatic Melanoma
Interventions
Aldesleukin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

NCT00733265
View directory record Official record
Conditions
Renal Impairment
Interventions
AZD6140
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Phoenix, Arizona • Anaheim, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2010 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT03038100
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Paclitaxel, Carboplatin, Atezolizumab, Bevacizumab, Atezolizumab Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
127
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 23, 2026, 11:29 AM EDT
Withdrawn Phase 1 Interventional

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

NCT00659399
View directory record Official record
Conditions
Ovarian Carcinoma
Interventions
Fondaparinux
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 23, 2026, 11:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

NCT03961932
View directory record Official record
Conditions
Renal Impairment, Healthy Participants
Interventions
Linzagolix
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 23, 2026, 11:29 AM EDT